Al Salamania
Al Salamania, River Nile, Sudan
NCT Number: NCT01558336
The purpose of this study is to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan.
Looking for future studies?
Notify Me6 year–15 year
All sexes
Interventional
Phase 3
Al Salamania, River Nile, Sudan
A longitudinal study will be conducted to evaluate the impact of praziquantel for the treatment of Schistosoma haematobium infection among schoolchildren in Al Salamania in Central Sudan. A cohort of schoolchildren (6-15 years of age) was investigated before and 1 year after treatment with a single dose of praziquantel 40mg/kg.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
praziquantel 40 mg/kg oral tablets
Time frame: one year
The reduction of the prevalence and intensity of S.haematobium infection following a single dose of praziquantel40mg/kg
Time frame: one year
will a single dose of PZQ significantly reduced intensity of infection of S. haematobium infection 1 year after treatment
University of Khartoum
Other
Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01512277
Bilharziasis, Female Urogenital Diseases
Lille, France
View Trial DetailsNCT01553552
Anemia, Body Weight
Saint-Louis, SL, Senegal
View Trial DetailsNCT05762393
Helminthiasis, Infections
Ouagadougou, Burkina Faso
View Trial DetailsNCT03640377
Helminthiasis, Infections
Entebbe, Uganda
View Trial Details